SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-032843
Filing Date
2023-07-13
Accepted
2023-07-13 16:00:59
Documents
18
Period of Report
2023-07-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20230711.htm   iXBRL 8-K 71274
2 EX-10.1 omga-ex10_1.htm EX-10.1 148486
3 EX-10.2 omga-ex10_2.htm EX-10.2 148957
4 EX-10.3 omga-ex10_3.htm EX-10.3 148805
5 GRAPHIC img33839852_0.jpg GRAPHIC 91618
6 GRAPHIC img34763373_0.jpg GRAPHIC 91618
7 GRAPHIC img35686894_0.jpg GRAPHIC 91618
  Complete submission text file 0000950170-23-032843.txt   1073146

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20230711_lab.xml EX-101.LAB 13350
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20230711_pre.xml EX-101.PRE 10995
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20230711.xsd EX-101.SCH 2479
12 EXTRACTED XBRL INSTANCE DOCUMENT omga-20230711_htm.xml XML 4711
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 231086784
SIC: 2836 Biological Products, (No Diagnostic Substances)